IL195295A - Use of phosphodiesterase inhibitors 4 for the preparation of drugs for the treatment of motor disability associated with traumatic brain injury - Google Patents

Use of phosphodiesterase inhibitors 4 for the preparation of drugs for the treatment of motor disability associated with traumatic brain injury

Info

Publication number
IL195295A
IL195295A IL195295A IL19529508A IL195295A IL 195295 A IL195295 A IL 195295A IL 195295 A IL195295 A IL 195295A IL 19529508 A IL19529508 A IL 19529508A IL 195295 A IL195295 A IL 195295A
Authority
IL
Israel
Prior art keywords
phosphodiesterase
medicaments
inhibitors
treating
manufacture
Prior art date
Application number
IL195295A
Other languages
English (en)
Hebrew (he)
Other versions
IL195295A0 (en
Original Assignee
Dart Neuroscience Cayman Ltd
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd, Helicon Therapeutics Inc filed Critical Dart Neuroscience Cayman Ltd
Publication of IL195295A0 publication Critical patent/IL195295A0/en
Publication of IL195295A publication Critical patent/IL195295A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
IL195295A 2006-05-19 2008-11-13 Use of phosphodiesterase inhibitors 4 for the preparation of drugs for the treatment of motor disability associated with traumatic brain injury IL195295A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80194906P 2006-05-19 2006-05-19
PCT/US2007/069279 WO2007137181A2 (en) 2006-05-19 2007-05-18 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

Publications (2)

Publication Number Publication Date
IL195295A0 IL195295A0 (en) 2009-08-03
IL195295A true IL195295A (en) 2015-11-30

Family

ID=38617977

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195295A IL195295A (en) 2006-05-19 2008-11-13 Use of phosphodiesterase inhibitors 4 for the preparation of drugs for the treatment of motor disability associated with traumatic brain injury

Country Status (11)

Country Link
EP (2) EP2021001B1 (https=)
JP (2) JP2009537568A (https=)
CN (1) CN101500559B (https=)
AU (1) AU2007253734B2 (https=)
BR (1) BRPI0711816A2 (https=)
CA (1) CA2653042C (https=)
ES (1) ES2412481T3 (https=)
IL (1) IL195295A (https=)
MX (1) MX2008014713A (https=)
SG (2) SG172602A1 (https=)
WO (1) WO2007137181A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316531A1 (en) * 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
KR20110049801A (ko) * 2008-07-18 2011-05-12 다트 뉴로사이언시즈, 엘엘씨 기억 물질의 평가를 위한 방법 및 시스템
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JP6325254B2 (ja) * 2011-09-30 2018-05-16 公益財団法人東京都医学総合研究所 サイクリックａｍｐ応答配列結合タンパク質遺伝子解析による薬物感受性および疾患脆弱性の評価方法
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
CA3103781C (en) * 2019-12-23 2023-02-14 Peter Anthony Hall Method and system for assessing cognitive function of an individual

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
EP0651824A4 (en) 1992-04-10 1997-02-26 Fox Chase Cancer Center TRANSCRIPTION ELEMENT FOR CONTROLLING THE INCREASED GENE EXPRESSION IN MYOBLASTEN.
JP2001508020A (ja) * 1994-06-02 2001-06-19 シエーリング アクチエンゲゼルシヤフト 多発性硬化症治療用のｐｄｅ ｉｖ阻害剤
US6689557B1 (en) 1994-10-07 2004-02-10 Cold Spring Harbor Laboratory Method of identifying a substance that affects long term memory and CREM/CREB/ATF-1 subfamily members
US5929223A (en) 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
DE69919179T2 (de) 1998-09-09 2005-07-28 Inflazyme Pharmaceuticals, Ltd., Richmond Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
EP1157007A1 (en) 1999-02-25 2001-11-28 Merck Frosst Canada Inc. Pde iv inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
EP2316531A1 (en) * 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Augmented cognitive training
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
EP1343528A2 (en) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
IL161317A0 (en) * 2001-10-16 2004-09-27 Memory Pharm Corp 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
EP1482916A4 (en) * 2002-02-07 2007-12-12 Univ Miami SCHWANNZELLEN AND PHOSPHODIESTERASE-HEMMER BASED THERAPY
DK1610796T3 (da) * 2003-03-17 2014-07-21 Neurohealing Pharmaceuticals Inc Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade
US20090298864A1 (en) * 2005-04-11 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for Treating Mild Cognitive Impairment

Also Published As

Publication number Publication date
SG10201407258RA (en) 2015-01-29
CN101500559B (zh) 2014-01-08
WO2007137181A2 (en) 2007-11-29
AU2007253734B2 (en) 2013-07-25
BRPI0711816A2 (pt) 2011-12-13
EP2021001B1 (en) 2012-12-12
HK1130656A1 (en) 2010-01-08
EP2377533A3 (en) 2012-02-22
AU2007253734A1 (en) 2007-11-29
EP2377533A2 (en) 2011-10-19
CN101500559A (zh) 2009-08-05
SG172602A1 (en) 2011-07-28
CA2653042A1 (en) 2007-11-29
JP2009537568A (ja) 2009-10-29
ES2412481T3 (es) 2013-07-11
WO2007137181A3 (en) 2008-08-07
EP2021001A2 (en) 2009-02-11
IL195295A0 (en) 2009-08-03
JP2015042667A (ja) 2015-03-05
CA2653042C (en) 2016-07-05
MX2008014713A (es) 2009-04-17

Similar Documents

Publication Publication Date Title
IL195295A (en) Use of phosphodiesterase inhibitors 4 for the preparation of drugs for the treatment of motor disability associated with traumatic brain injury
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
IL195571A0 (en) Compounds for the treatment of periodontal disease
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL182104A (en) Apparatus for altering the body temperature of a patient
IL197169A0 (en) Use of fgf-18 in the manufacture of a medicament for treatment of cartilage disorders
ZA200805716B (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
ZA201005223B (en) Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AP2488A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
ZA201005220B (en) Use of anti-connexin polynucleotides for the treatment of surgical adhesions
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL198967A0 (en) Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
EP2068789A4 (en) DEVICE FOR CHANGING THE BODY TEMPERATURE OF A PATIENT
ZA200900556B (en) Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders
PL1842537T3 (pl) Zastosowanie związku przeciw zakrzepom miażdżycowym do wytwarzania leku do leczenia zaburzeń naczyniowo-mózgowych
SI1868614T1 (sl) Odmerni režim za zdravljenje travmatske možganske poškodbe s progesteronom
GB0604772D0 (en) Use of substituted amine compounds for the treatment of food related disorders
GB0604778D0 (en) Use of substituted amine compouds fo the treatment of food related disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed